Fecal calprotectin assay for monitoring disease activity in Crohn disease
HAYES, Inc
Record ID 32018000030
English
Authors' recommendations:
Mucosal healing is emerging as a primary therapeutic target for Crohn disease (CD), as a growing body of evidence suggests that it is associated with better patient outcomes. The definitive standard for assessing intestinal inflammation is ileocolonoscopy; however, this technique is invasive, time consuming, expensive, and carries a risk of complications. Calprotectin is a specific, neutrophilderived, calcium-binding protein that can be measured in small stool samples and used as a marker of intestinal inflammation. Rationale: Fecal calprotectin (FC) testing may provide a noninvasive, cost-effective alternative to ileocolonoscopy to predict and monitor disease activity in patients with CD.
Controversy:
While FC testing presents a noninvasive approach for monitoring disease activity, it has several potential disadvantages, including: diminished value in patients with CD restricted to the small bowel; imperfect correlation with transmural inflammation; and elevation of levels due to infectious enterocolitis, colorectal cancer, or use of nonsteroidal anti-inflammatory drugs, potentially leading to false-positive FC results. Moreover, optimal FC cutoff values to distinguish endoscopically active disease, endoscopic remission, or clinical relapse have yet to be established.
Relevant Questions:
What is the clinical validity of the FC assay to predict and monitor disease activity in CD? What is the clinical utility of the FC assay to predict and monitor disease activity in CD? Is FC testing safe for use in patients with CD? Have definitive patient selection criteria been established for use of FC to predict and monitor CD?
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
The report may be purchased from:
http://www.hayesinc.com/hayes/crd/?crd=15795
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Biological Assay
- Crohn Disease
- Feces
- Humans
- Inflammatory Bowel Diseases
- Leukocyte L1 Antigen Complex
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.